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Abstract
Breast carcinoma with osteoclastic giant cells (OGCs) is characterized by multinucleated OGCs, and usually displays
inflammatory hypervascular stroma. OGCs may derive from tumor-associated macrophages, but their nature
remains controversial. We report two cases, in which OGCs appear in common microenvironment despite different
tumoural histology. A 44-year-old woman (Case 1) had OGCs accompanying invasive ductal carcinoma, and an
83-year-old woman (Case 2) with carcinosarcoma. Immunohistochemically, in both cases, tumoural and non-
tumoural cells strongly expressed VEGF and MMP12, which promote macrophage migration and angiogenesis. The
Chalkley count on CD-31-stained sections revealed elevated angiogenesis in both cases. The OGCs expressed bone-
osteoclast markers (MMP9, TRAP, cathepsin K) and a histiocyte marker (CD68), but not an MHC class II antigen,
HLA-DR. The results indicate a pathogenesis: regardless of tumoural histology, OGCs derive from macrophages,
likely in response to hypervascular microenvironments with secretion of common cytokines. The OGCs have
acquired bone-osteoclast-like characteristics, but lost antigen presentation abilities as an anti-cancer defense.
Appearance of OGCs may not be anti-tumoural immunological reactions, but rather pro-tumoural differentiation of
macrophage responding to hypervascular microenvironments induced by breast cancer.
Background
Breast carcinoma with osteoclastic giant cells is a rare
entity that falls under the WHO classification of invasive
ductal carcinoma, not otherwise specified [1]. This
tumor is characterized by the presence of osteoclastic
giant cells (OGCs), the nature of which remains contro-
versial. OGCs accompany a variety of breast tumors,
including invasive ductal carcinoma and cribriform, tub-
ular, mucinous, papillary, lobular, squamous, and other
metaplastic patterns. Despite divergent tumor histology,
most cases present a well-demarcated mass with charac-
teristic inflammatory and hypervascular stroma [2].
OGCs are agreed to be of histiocytic origin, and are
hypothesized to derive from macrophages [3]. Macro-
phages display marked plasticity with both pro-tumoural
and anti-tumoural activities [4-6]. Their classical anti-
tumoural roles include promotion of specific immunity
by inducing T cell activation via antigen presentation.
Recent studies have also focused on their direct or indir-
ect pro-tumoural functions: enhancement of angiogen-
esis and cancer cell growth and spread [4,6].
Macrophages secrete growth factors such as epidermal
growth factor (EGF) and vascular endothelial growth
factor (VEGF), and produce proteases including matrix
metalloproteinases (MMPs). Both VEGF and MMP12
enhance macrophage migration [7,8], and VEGF also
regulates angiogenesis and lymphangiogenesis through
different types of receptors. Microenvironments, with
secretion of cytokines, seem to affect progression of
breast cancer [9,10], and may also determine whether
OGCs are formed. However, in current thinking, the
prognosis of breast carcinoma with OGCs is considered
to be related to the tumoural histology, and not influ-
enced by the presence of OGCs [1].
Here, we report two cases of breast carcinoma with
OGCs associated with invasive ductal carcinoma
(Case 1) or carcinosarcoma (Case 2). Despite different
tumoural histology, two cases displayed common micro-
environments with expression of VEGF and MMP12,
suggesting enhanced macrophage migration and
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blance to the osteoclasts in the bone, and lacked antigen
presentation abilities. Macrophage plasticity responding
microenvironments is discussed, in relation to prognosis
of breast carcinoma.
Case Presentation
Case 1: A 44-year-old woman presented with a lump in
the lower inner quadrant of her right breast. Physical
examination revealed a well-demarcated firm tumor
with good mobility. Mammography and ultrasonography
revealed a well-circumscribed tumor of 30 × 20 ×
25 mm, and magnetic resonance imaging (MRI) showed
rich vascularity, especially in the periphery. Fine-needle
aspiration and core needle biopsy demonstrated invasive
ductal carcinoma with multi-nucleated OGCs. Partial
mastectomy was performed following sentinel lymph
node biopsy. There was no metastasis to the sentinel
lymph nodes, and the postoperative stage was pT2 N0
M0, stage IIA.
Case 2: An 83-year-old woman presented with a painful
lump in the upper inner quadrant of her right breast.
Ultrasonography revealed a well-defined mass of 19 × 16 ×
10 mm. Both mammography and MRI suggested malig-
nancy. As the specimen of aspiration cytology did not con-
tain enough epithelial cells for diagnosis, an intraoperative
frozen section was examined, leading to diagnosis of malig-
nant tumor. Partial mastectomy was performed, and the
final pathologic diagnosis was beast carcinoma with OGCs.
The postoperative stage for this patient was also pT2 N0
M0, stage IIA.
Materials and methods
For histological analysis, the surgical specimens were
fixed in 10% buffered formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin. For
immunohistochemical analysis, the sections were depar-
afinized and reacted with primary antibodies, followed
by the immunoperoxidase method with a commercial
kit (DakoCytomation Co Ltd, Glostrup, Denmark). The
primary antibodies used in this study are as follows: ER
(1D5, 1:100, Dako), PgR (PgR636, 1:400, Dako), HER2
(polyclonal, 1:1, Dako), CKAE1/AE3 (AE1/AE3, 1:100,
Dako), Vimentin (V9, 1:2, Nichirei), VEGF (A-20, 1:400,
Santacruz), MMP9 (polyclonal, 1:5000, Abcam), MMP12
(polyclonal, 1:100, Abcam), CD31 (JC70A, 1:50, Dako),
C D 6 8( P G M - 1 ,1 : 1 0 0 ,D a k o ) ,H L A - D R( T A L 1 B 5 ,1 : 1 0 0 ,
Dako), TRAP (26E5, 1:100, Novocastra), Cathepsin K
(182-12G5, 1:10000, Dai-ichi fain chemical).
Results
Gross and microscopic findings
Case 1 grossly showed a well-circumscribed solid tumor,
measuring 3.5 × 2.5 cm on the maximum cut plane.
The tumor appeared gray to white in the center, but
hemorrhagic dark brown at the periphery (Figure 1A).
Microscopically, the tumor was surrounded by hypere-
mic blood vessels (Figure 1B). The ductal carcinoma
cells, which had relatively small and round nuclei with
m i l da t y p i aa n di n f r e q u e n tm i t o s i s ,f o r m e dd i s t i n c t
glandular and cribriform structures, equivalent to inva-
sive ductal carcinoma, grade 1 (well-differentiated)
(Figure 1C, D). The hypervascular stroma contained
numerous inflammatory cells and multinucleated giant
cells (Figure 1E). Some giant cells showed a polarized
cell body resembling activated osteoclasts (Figure 1F).
Immunohistochemically, strong staining for cytokeratin
(CK) AE1/AE3 was observed in all tumor cells, but not
in OGCs (Figure 1G). About 40% of tumor cells were
positive for estrogen receptor (ER) (Figure 1H) and
progesterone receptor (PgR), but negative for HER2,
phenotypically corresponding to Luminal A type. Fol-
lowing the WHO classification, the diagnosis was breast
carcinoma with OGCs.
The tumor in Case 2 also showed a well-circumscribed
gross appearance, measuring 2.2 × 1.5 cm on the maxi-
mum cut plane. The tumor was rather whitish, but con-
tained a small (5 mm) hemorrhagic area (Figure 1I).
Microscopically, the main part of tumor consisted of
spindle-shaped sarcomatous cells with frequent mitotic
figures, and there were also foci of ductal carcinoma cells
with an intraductal component (Figure 1J-L). Inflamma-
tory cells and multinucleated OGCs were seen in the
hypervascular stroma (Figure 1M, N). Immunohisto-
chemically, the ductal carcinoma cells were positive for
CK AE1/AE3 (Figure 1O) but not ER, PgR, or HER2. The
spindle-shaped tumor cells constituting most of the
tumor were not reactive for CK AE1/AE3, but instead
were strongly positive for vimentin (Figure 1P). Thus, the
case was diagnosed as breast carcinoma with OGCs, and
the tumor was equivalent to metaplastic carcinoma with
mesenchymal component, corresponding to so-called
carcinosarcoma.
Topography of CD68-positive cells and expression of
chemotactic agents
Despite the different histological features of the breast
carcinoma cells, the OGCs in both cases showed similar
morphology, and large OGCs contained 20-30 nuclei. In
both cases, OGCs preferentially appeared in hypervascu-
lar stroma, but the topography of OGCs and blood ves-
sels differed between Case 1 and Case 2. In Case 1,
CD31 immunostaining demonstrated that the smaller
blood vessels were relatively evenly distributed within
the tumor; in contrast, numerous enlarged blood vessels
were seen in the periphery (Figure 2A). Large OGCs
with over 20 nuclei showed concentric topography; they
were mainly seen in the central invasive lesion, while
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were usually observed in the periphery (Figure 2B).
Typical OGCs containing more than 20 nuclei were
scarcely detected in the intraductal components,
although some CD68-positive cells, including mono-,
bi- or trinucleate cells, were seen within the ducts
(Figure 2C). In Case 2, unlike Case 1, the distribution of
OGCs and blood vessels was irregular, not concentric.
OGCs were usually clustered in irregularly distributed
hypervascular areas (Figure 2D). Mono-, bi-, tri-, or oli-
gonucleated cells were also observed around the OGCs
(Figure 2E). However, CD68-positive cells, regardless of
the number of the nuclei, were scarcely seen within the
minor intraductal lesions (Figure 2F).
To assess the microenvironment of the tumors, we
examined the expression of two chemoattractants for
macrophage migration and angiogenesis, VEGF and
MMP12. Prominent expression of VEGF and MMP12
was observed in most tumor cells, most inflammatory
cells, and even neighboring normal mammary glands
both in Case 1 and Case 2 (Figure 2G-R). The OGCs, in
both cases, also displayed marked expression of VEGF
and MMP12.
Statistic evaluation of microvessel density
In hypervascular stroma of both cases, microvessel den-
sity was evaluated according to the Chalkley count on
CD-31-stained sections, as described earlier. The mean
values of the three most vascular areas (hot spot) were
9.6 for Case 1 and 10.7 for Case 2, respectively. These
counts were much higher than the average Chalkley
count of a total 330 invasive breast carcinoma cases,
5.75 (range 2.33 - 10.67, median 5.67, SD 1.54), reported
in a previous study[11,12].
Figure 1 Gross and microscopic findings of breast carcinoma with OGCs. OGCs in Case 1 appeared associated with invasive ductal
carcinoma, grade 1, and in Case 2 with carcinosarcoma. A-H: Case 1. A: Gross appearance. B: Low power view of the tumor. C, D: High power
views of the tumor. E, F: Bi-, tri-, tetranucleate cells were observed as well as OGCs in hypervascular inflammatory stroma. G: CK AE1/AE3
staining. H: ER staining. I-N: Case 2, corresponding to A-F in Case 1. O: CK AE1/AE3 staining. P: Vimentin staining.
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in both cases OGCs preferentially appeared in hypervascular stroma. Marked expression of VEGF and MMP12 was evident. A: Distribution of
blood vessels marked with CD31 in Case 1. B, C: CD68-positive cells in Case 1. D: Distribution of blood vessels marked with CD31 in Case 2. E, F:
CD68-positive cells in Case 2. G-R: VEGF and MMP12 expression in Case 1 (G-L), and Case 2 (M-R).
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Phenotypic characteristics of OGCs in the two cases
were evaluated and compared with those of osteoclastic
cells in fibrous dysplasia of the rib bone (from a 45-
year-old woman) and foreign-body giant cells in re-
operated breast tissue (a 42-year-old woman). CD68, a
histiocytic marker, was detected on all macrophage line-
age cells, including OGCs and oligonucleated giant cells
in both Case 1 and Case 2, osteoclastic cells in the bone
sample, and foreign-body giant cells (Figure 3A-D).
MMP9 is a broad marker for macrophage-osteoclast
lineage cells, including mononuclear precursors, fused
polykaryons, and mature osteoclasts in bone. MMP9
expression was distinctly detected in the osteoclastic
c e l l s( F i g u r e3 E )a n dt h eO G C si nC a s e1( F i g u r e3 F ) ,
but markedly weaker in Case 2 (Figure 3G) and foreign-
body giant cells (Figure 3H). TRAP and cathepsin K,
lytic enzymes for bone resorption, are functional mar-
kers for osteoclast-lineage cells. Their expression was
distinct in the osteoclastic cells and the OGCs in both
Case 1 and Case 2 (Figure 3I-K, M-O). Unexpectedly,
foreign body giant cells were also strongly positive for
Figure 3 Expression of phenotypic markers of OGCs. Phenotypes of OGCs in the breast (center panels) were compared those of osteoclastic
cells in the bone (far left) and foreign body giant cells (far right). OGCs in the breast displayed both osteoclastic and histiocytic characteristics
but lacked antigen presentation abilities. A-D: CD68, a phenotypic marker for histiocytes. E-H: MMP9, a broad marker for macrophage-osteoclast
lineage cells. I-L: TRAP. M-P: Cathepsin K. Q-T: HLA-DR.
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cathepsin K (Figure 3P). HLA-DR, an MHC class II anti-
gen, is generally expressed in antigen-presenting cells
including macrophages and peripheral blood mononuc-
lear cells. Only foreign body giant cells were positive for
HLA-DR; the bone osteoclasts and OGCs were negative
(Figure 3Q-T).
Discussion
In this study, we demonstrated that the OGCs appear in
relation to inflammatory hypervascular stroma around
breast carcinoma regardless of histology. Abundant
VEGF and MMP12 were secreted from both tumoural
and non-tumoural cells, and these cytokines promote
macrophage migration and angiogenesis. Notable
increase of microvessel density was actually shown by
the Chalkley count in inflammatory stroma of both
cases. The OGCs are likely generated by syncytial fusion
of macrophages, but not by mitosis without cell division.
Thus, bi-, tri-, or oligo-nuclear CD-68 positive cells were
scattered around OGCs, but nuclear mitotic figures were
not observed. Phenotypic resemblance of OGCs to the
osteoclasts in the bone was confirmed with expression
of MMP9, TRAP, and cathepsin K. The OGCs were
negative for HLA-DR, and lacked antigen presentation
abilities as anti-cancer defence.
Macrophages are multifunctional, showing marked phe-
notypic plasticity in response to microenvironments.
Indeed, tumor-associated macrophages (TAMs) isolated
from breast cancer in vitro differentiated into multinu-
cleated giant cells with bone resorption [3]. A characteris-
tic inflammatory and hypervascular stroma is commonly
observed in breast carcinoma with OGCs, regardless of
histology of tumoural cells. This characteristic stroma may
indicate secretion of specific cytokines, and we, in this
study, first demonstrated marked expression of VEGF and
MMP12. Therefore, appearance of OGCs may not be anti-
tumoural immunological reactions, but rather pro-
tumoural differentiation of macrophage responding to
hypervascular microenvironments induced by breast can-
cer. However, the further case series study is necessary to
elucidate the prognostic or biological significance of
OGCs in association with breast carcinoma.
In the bone tissue, osteoclast differentiation seems
tightly associated with signaling related to RANKL
(receptor activator of nuclear factor-B ligand) [13], or
VEGF and its receptor Flt-1 [14]. Flt-1, expressed on
human monocyte/macrophage lineage cells [15], also reg-
ulates macrophage migration in response to VEGF [7].
To test for such differentiation signaling in the OGCs in
the breast, we also examined expression of RANKL and
Flt-1. Weak but distinct expression of Flt-1 was detected
in the OGCs of both Case 1 and Case 2, but expression
of RANKL was not clear (data not shown). Thus, it is still
uncertain if osteoclast differentiation signaling function
in the breast, mimicking in the bone.
Conclusion
The OGCs likely develop from macrophages in response
to pro-tumoural microenvironment defied by cytokines,
favoring macrophage migration and angiogenesis. The
OGCs have acquired bone-osteoclast-like characteristics,
but no more have antigen presentation abilities as anti-
cancer defence. Macrophages and angiogenesis may
imply the poor prognosis of the breast cancer [16,17].
Therefore, the appearance of OGCs is not merely histio-
cytic reactions, but better taken as a part of pathology
of breast tumours.
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